Pdude. we can respectfully disagree . Dr Bhatt IMHO involvement in MITIGATE was not because it was largely a Covid trial . Name another Covid trial he was part of. His interest IMHO is largely the exploratory CV endpoints ....which he knows , if the trial is / was run long enough ...can independently confirm to some degree the US-R-IT portion of his Reduce It trial . Until we get some degree of independent confirm of some of the R-IT results ...Vascepa scripts both brand and generic go sideways at best in the US . Vazkepa in the UK and EU will be a losing proposition ( costs will exceed income ) . JMO Kiwi